Lotemax® Gel
Loteprednol 0.5% · ophthalmic gel
Steroid
Approved uses
Post-operative inflammation and pain following ocular surgery
1 to 2 drops into the conjunctival sac of the affected eye QID beginning the day after surgery, continuing through the first 2 post-operative weeks
By day 8, 74% are pain free and 31% have complete anterior chamber cell clearance.
Post-operative inflammation and pain following ocular surgery in pediatric patients
Labeled regimen applies: 1 to 2 drops QID beginning the day after surgery through the first 2 post-operative weeks. The supporting pediatric trial dosed four times daily for 14 days
Matches prednisolone acetate 1% for day-14 inflammation in children 11 and under.
OFF-LABELNot in the FDA label for this product
Corticosteroid prophylaxis after photorefractive keratectomy
QID for 1 week, then TID for 3 weeks, then BID for 1 month, then QD for 1 month
Comparative trial · n=132
Single-center prospective, randomized, partially masked trial, 261 eyes of 132 patients, comparing this 3-month gel taper with prednisolone acetate 1% tapered to fluorometholone 0.1%; examiners were masked for IOP and haze grading. Corneal haze in the first 3 months occurred in 3 of 114 eyes on gel versus 7 of 147 on the comparator, and an IOP rise of 10 mmHg or more above baseline or any IOP above 21 mmHg in 2 of 114 versus 6 of 147; neither difference reached statistical significance. Visual and refractive results were equivalent, and the authors concluded only that the gel taper is clinically noninferior, not superior.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
0.5% gel (loteprednol etabonate 5 mg/g), 5 g in a 10 mL bottle
Corticosteroid: binds and activates the glucocorticoid receptor and is thought to inhibit prostaglandin production through several independent mechanisms, inhibiting the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation, while probably delaying healing. Lipid soluble and structurally engineered from prednisolone-related compounds for predictable breakdown to the inactive carboxylic acid metabolites PJ-90 and PJ-91; systemic exposure after ocular dosing of this gel has not been studied in humans.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may result in glaucoma with optic nerve damage and defects in visual acuity and visual fields; use with caution in the presence of glaucoma, and monitor IOP if this product is used 10 days or longer.
- Posterior subcapsular cataract: Corticosteroid use may produce it.
- Delayed healing after cataract surgery: Steroids used after cataract surgery may delay healing and increase the incidence of bleb formation.
- Corneal or scleral perforation: In diseases causing thinning of the cornea or sclera, perforations have occurred with topical steroids.
- Prescription renewal: Initial prescription and renewal only after examination with magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. This label sets no day count for the gate.
- Secondary ocular infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions of the eye steroids may mask infection or enhance existing infection.
- Viral infection exacerbation: Ocular steroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution.
- Fungal keratitis: Fungal corneal infection is particularly prone to develop coincidentally with long-term local steroid use; consider fungal invasion in any persistent corneal ulceration where a steroid has been used or is in use, and culture when appropriate.
- Contact lens wear: Lenses should not be worn during the course of therapy.
Common Side Effects
The most common adverse drug reactions reported in the clinical trials (2% to 5%) were anterior chamber inflammation, eye pain, and foreign body sensation. Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing and secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.
Pregnancy: No adequate and well controlled studies in pregnant women. Oral dosing produced teratogenicity at clinically relevant doses, with malformations in rabbits from 1.2 times the recommended human ophthalmic dose (spina bifida including meningocele from 0.1 mg/kg, exencephaly and craniofacial malformations from 4.9 times) and in rats from 30 times. Abortion and embryofetal lethality (resorption) occurred in rabbits from 73 times, and offspring survival was reduced in rats from 3 times. Background risk in the U.S. general population is 2% to 4% for major birth defects and 15% to 20% for miscarriage.
Lactation: No data on the presence of drug in human milk, on effects in the breastfed infant, or on milk production; weigh the developmental and health benefits of breastfeeding against the clinical need and potential adverse effects.
Safety and effectiveness established in pediatric patients. Use in this population is supported by adequate and well-controlled trials in adults, with additional data from a safety and efficacy trial in pediatric patients from birth to 11 years of age.